1. Search Result
Search Result
Results for "

dimerization of PD-L1

" in MedChemExpress (MCE) Product Catalog:
Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-134884
    INCB086550
    2 Publications Verification

    PD-1/PD-L1-IN-8

    PD-1/PD-L1 Cancer
    INCB086550 is a potent, oral, small-molecule PD-L1 inhibitor with IC50s value of 3.1, 4.9 and 1.9 nM for human, cynomolgus, and rat, respectively. INCB086550 promotes the dimerization of cell-surface PD-L1 and induces PD-L1 entry into Golgi vesicles then traffick to the nucleus. INCB086550 can be used for multiple cancers research .
    INCB086550
  • HY-102011
    BMS-1166
    Maximum Cited Publications
    6 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
    BMS-1166
  • HY-124700
    LYPLAL1-IN-1
    1 Publications Verification

    Cyclic GMP-AMP Synthase STING PD-1/PD-L1 Epoxide Hydrolase Metabolic Disease
    LYPLAL1-IN-1 (compound 11) is a selective, covalent, and irreversible inhibitor of the lysophospholipase-like enzyme LYPLAL1 (IC50 = 6 nM). LYPLAL1-IN-1 shows selectivity against other serine hydrolases such as carboxylesterase CES1 (IC50 > 50 μM for CES1). LYPLAL1-IN-1 inhibits the depalmitoylation function of LYPLAL1, blocking its depalmitoylation modification of cyclic GMP-AMP synthase (cGAS), thereby promoting cGAS dimerization and activation, and initiating the cGAS-STING pathway-mediated innate immune response. LYPLAL1-IN-1 can enhance DNA-induced type I interferon production, upregulate PD-L1 expression in tumor cells, and promote the accumulation of tumor-infiltrating CD8 + T cells, with the core function of strengthening the anti-tumor immune response. LYPLAL1-IN-1 is primarily used in tumor immunology research, especially in combination with PD-1/PD-L1 inhibitors .
    LYPLAL1-IN-1
  • HY-120402

    PD-1/PD-L1 Inflammation/Immunology
    BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 80 nM. BMS-200 can induce dimerization of PD-L1 .
    BMS-200
  • HY-144258

    PD-1/PD-L1 Inflammation/Immunology Cancer
    PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of PD-1/PD-L1 interactions, with an IC50 of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .
    PD-1/PD-L1-IN-14
  • HY-152240

    PD-1/PD-L1 Cancer
    PD-1/PD-L1-IN-29 (S4-1) is a potent PD-1/PD-L1 inhibitor with an IC50 value of 6.1 nM. PD-1/PD-L1-IN-29 binds PD-L1 and disrupts PD-1/PD-L1 interactions, induces PD-L1 dimerization and internalization, improves its localization to the endoplasmic reticulum, and promotes PD-L1 entry into the endoplasmic reticulum. PD-1/PD-L1-IN-29 has anticancer activity .
    PD-1/PD-L1-IN-29
  • HY-102011A
    BMS-1166 hydrochloride
    Maximum Cited Publications
    6 Publications Verification

    PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1166 hydrochloride is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 hydrochloride induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 hydrochloride antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
    BMS-1166 hydrochloride
  • HY-102011R

    Reference Standards PD-1/PD-L1 Inflammation/Immunology Cancer
    BMS-1166 (Standard) is the analytical standard of BMS-1166 (HY-102011). This product is intended for research and analytical applications. BMS-1166 is a potent PD-1/PD-L1 immune checkpoint inhibitor. BMS-1166 induces dimerization of PD-L1 and blocks its interaction with PD-1, with an IC50 of 1.4 nM. BMS-1166 antagonizes the inhibitory effect of PD-1/PD-L1 immune checkpoint on T cell activation .
    BMS-1166 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: